The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Alexander J EustaceS F MaddenJ FayD M CollinsE W KayK M SheehanS FurneyB MoranA FaganP G MorrisA TeiserskieneA D HillL GroganJ M WalsheO BreathnachC PowerD DukeK EganW M GallagherN O'DonovanJ CrownS ToomeyB T HennessyPublished in: Breast cancer research and treatment (2021)
The immune system may be 'primed' prior to neoadjuvant treatment in those patients who subsequently achieve a pCR. In those patients who achieve a pCR, their immune response may return to baseline after only 1 cycle of treatment. However, in those who did not achieve a pCR, neo-adjuvant treatment may stimulate lymphocyte influx into the tumour.